Coffee Interaction With the Antihypertensive Drug Felodipine

NCT ID: NCT02232269

Last Updated: 2018-08-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-29

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Coffee is a globally popular beverage. More than half of the United States population spends an estimated $ 40 billion on the purchase of coffee each year. Personal consumption habits can vary. For example, the frequency of ingestion ranged from 59% for every day to 8% for less than one day per week consumption in one survey. In the case of occasional consumption, coffee can markedly elevate blood pressure in normotensive and hypertensive individuals. This pressor effect can occur with a caffeine dose of 200 - 250 mg, which can be found 2 - 3 cups of coffee. A major active constituent in coffee is caffeine, which is the most widely used pharmacological substance in the world.

Drug therapy plays a major role in the management of hypertension. However, the interaction between coffee or caffeine and blood pressure lowering drugs has been assessed in only three clinical studies that were reported more than three decades ago.

We conducted a comprehensive interaction study involving a commonly ingested amount of a particular Colombian coffee and felodipine in healthy middle-aged men and women. Peripheral (brachial) and central (aortic) hemodynamics and caffeine and felodipine pharmacokinetics were evaluated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Food-Drug Interactions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Water plus Felodipine

Felodipine extended-release tablet ,10 mg, single dose, 8 hours

Group Type PLACEBO_COMPARATOR

Water

Intervention Type OTHER

Felodipine

Intervention Type DRUG

Black Coffee

Black Coffee, 300 ml, 0 and 1 hour

Group Type ACTIVE_COMPARATOR

Black Coffee

Intervention Type OTHER

Black Coffee plus Felodipine

Black Coffee, 300 ml, 0 and 1 hour

Felodipine extended-release tablet ,10 mg, single dose, 8 hours

Group Type EXPERIMENTAL

Black Coffee

Intervention Type OTHER

Felodipine

Intervention Type DRUG

Grapefruit Juice plus Felodipine

Grapefruit Juice, 300 ml, 0 and 1 hour

Felodipine extended-release tablet ,10 mg, single dose, 8 hours

Group Type ACTIVE_COMPARATOR

Grapefruit Juice

Intervention Type OTHER

Felodipine

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Black Coffee

Intervention Type OTHER

Grapefruit Juice

Intervention Type OTHER

Water

Intervention Type OTHER

Felodipine

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Plendil Renadil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy (normal physical exam, blood clinical chemistry)
* willingly signs ethics approved informed consent form

Exclusion Criteria

* history of cardiac, renal, hepatic or gastrointestinal disease or substance abuse
* significant illness within 2 weeks of starting study
* history of allergy to felodipine , tablet ingredients or dihydropyridines
* routinely taking prescription or OTC drugs or natural health products
* received an investigational drug withing the previous 4 weeks
* females who are pregnant or breast-feeding
Minimum Eligible Age

30 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

David Bailey

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David G Bailey, BScPhm, PhD

Role: PRINCIPAL_INVESTIGATOR

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Victoria Clinical Trials Centre

London, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Bailey DG, Dresser GK, Urquhart BL, Freeman DJ, Arnold JM. Coffee-Antihypertensive Drug Interaction: A Hemodynamic and Pharmacokinetic Study With Felodipine. Am J Hypertens. 2016 Dec 1;29(12):1386-1393. doi: 10.1093/ajh/hpw081.

Reference Type BACKGROUND
PMID: 27481881 (View on PubMed)

Dresser GK, Urquhart BL, Proniuk J, Tieu A, Freeman DJ, Arnold JM, Bailey DG. Coffee inhibition of CYP3A4 in vitro was not translated to a grapefruit-like pharmacokinetic interaction clinically. Pharmacol Res Perspect. 2017 Oct;5(5):e00346. doi: 10.1002/prp2.346.

Reference Type BACKGROUND
PMID: 28971609 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NA-7122

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

R-11-655

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Coffee Polyphenols Antioxidants
NCT01832662 COMPLETED NA